Gadoxetic acid (Gd-EOB-DTPA)-enhanced mri versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: An initial experience

Korean Journal of Radiology

Volumn 11, Issue 4, 2010, Pages 433-440

  Park, Yulri ^a,b   Kim, Seong Hyun ^a   Kim, Seung Hoon ^a   Jeon, Yong Hwan ^c   Lee, Jongmee ^d   Kim, Min Ju ^d   Choi, Dongil ^a   Lee, Won Jae ^a   Kim, Heejung ^a   Koo, Ji Hyun ^a   Lim, Hyo Keun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c Kangwon National University College of Medicine   (South Korea)

^d Korea University College of Medicine   (South Korea)

Author keywords

Gadobenate dimeglumine enhanced MRI; Gadoxetic acid enhanced MRI; Hepatocellular carcinoma (HCC)

Indexed keywords

CONTRAST MEDIUM; GADOBENIC ACID; GADOXETIC ACID;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; LIVER SURGERY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PREOPERATIVE EVALUATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY ANALYSIS; SIGNAL NOISE RATIO;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 77954767195     PISSN: 12296929     EISSN: None     Source Type: Journal    
DOI: 10.3348/kjr.2010.11.4.433     Document Type: Article

References (33)

1. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, Negishi C, Weinmann HJ, Speck U. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 1992;183:59-64
2. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp 1. J Pharmacol Exp Ther 1999;290:153-157
3. de Haen C, Gozzini L. Soluble-type hepatobiliary contrast agents for MR imaging. J Magn Reson Imaging 1993;3:179-186
4. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglu-mine (Gd-BOPTA). An overview. Invest Radiol 1998;33:798-809
5. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharma-cologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 1999;6:282-291
6. Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging. Invest Radiol 1993;28:753-761
7. Spinazzi A, Lorusso V, Pirovano G, Taroni P, Kirchin M, Davies A. Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 1998;5:S86-S89
8. Hamm B, Staks T, Muhler A, Bollow M, Taupitz M, Frenzel T, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepato-biliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;195:785-792
9. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004;14:559-578
10. Hwang HS, Kim SH, Jeon TY, Choi D, Lee WJ, Lim HK. Hypointense hepatic lesions depicted on gadobenate dimeglu-mine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy. Korean J Radiol 2009;10:294-302
11. Kim YK, Kim CS, Chung GH, Han YM, Lee SY, Chon SB, et al. Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR Am J Roentgenol 2006;186:149-157
12. Kim YK, Kim CS, Lee YH, Kwak HS, Lee JM. Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas. AJR Am J Roentgenol 2004;182:1217-1223
13. Kim SH, Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009;192:1675-1681
14. Baron RL, Oliver JH, 3rd, Dodd GD, 3rd, Nalesnik M, Holbert BL, Carr B. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology 1996;199:505-511
15. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236
16. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430
17. Jang HJ, Lim JH, Lee SJ, Park CK, Park HS, Do YS. Hepatocellular carcinoma: are combined CT during arterial portography and CT hepatic arteriography in addition to triple-phase helical CT all necessary for preoperative evaluation? Radiology 2000;215:373-380
18. Kang BK, Lim JH, Kim SH, Choi D, Lim HK, Lee WJ, et al. Preoperative depiction of hepatocellular carcinoma: ferumox-ides-enhanced MR imaging versus triple-phase helical CT. Radiology 2003;226:79-85
19. Sherman M. Diagnosis of small hepatocellular carcinoma. Hepatology 2005;42:14-16
20. Bolondi L, Gaiani S, Celli N, Golfieri R, Grigioni WF, Leoni S, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005;42:27-34
21. Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT--initial observations. Radiology 2005;234:468-478
22. Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009;44:793-798
23. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-843
24. McNeil BJ, Hanley JA, Funkenstein HH, Wallman J. Paired receiver operating characteristic curves and the effect of history on radiographic interpretation. CT of the head as a case study. Radiology 1983;149:75-77
25. Bennett BM. On comparisons of sensitivity, specificity and predictive value of a number of diagnostic procedures. Biometrics 1972;28:793-800
26. Fleiss JL. The measurement of interrater agreement. In: Fleiss JL, ed. Statistical methods for the rates and proportions, 2nd ed. New York, NY: John Wiley & Sons, 1981:212-236
27. Uematsu H, Takahashi M, Dougherty L, Hatabu H. High field body MR imaging: preliminary experiences. Clin Imaging 2004;28:159-162
28. Ludeke KM, Roschmann P, Tischler R. Susceptibility artefacts in NMR imaging. Magn Reson Imaging 1985;3:329-343
29. Kurihara Y, Yakushiji YK, Tani I, Nakajima Y, Van Cauteren M. Coil sensitivity encoding in MR imaging: advantages and disadvantages in clinical practice. AJR Am J Roentgenol 2002;178:1087-1091
30. Chang JM, Lee JM, Lee MW, Choi JY, Kim SH, Lee JY, et al. Superparamagnetic iron oxide-enhanced liver magnetic resonance imaging: comparison of 1.5 T and 3.0 T imaging for detection of focal malignant liver lesions. Invest Radiol 2006;41:168-174
31. Sun HY, Lee JM, Shin CI, Lee DH, Moon SK, Kim KW, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or = 2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010;45:96-103
32. Kim JI, Lee JM, Choi JY, Kim YK, Kim SH, Lee JY, et al. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 2008;43:202-210
33. Yoon SH, Lee JM, So YH, Hong SH, Kim SJ, Han JK, et al. Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter: tumor size and cellular differentiation. AJR Am J Roentgenol 2009;193:W482-W489